Prof. Fang Liu 刘芳
Chief Physician, Professor
Department of Medical Oncology (II), Harbin Medical University Cancer Hospital, Harbin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical oncology for lung and other thoracic tumors, including molecular targeted therapy, chemotherapy, and immunotherapy. Expertise in perioperative adjuvant care, advanced-stage individualized treatment, malignant pleural and ascitic effusions, and multidisciplinary management.
Dr. Liu holds a PhD in Oncology and a Master’s in Internal Medicine. With 12 years in medical oncology, Dr. Liu focuses on thoracic malignancies, tumor microenvironment, and metastasis. Research includes one National Natural Science Foundation project. Published over 30 SCI papers in the last five years.
Professional roles
- Member, Chinese Society of Clinical Oncology (CSCO) Clinical Collaboration Center
- Member, Lung Cancer Professional Committee, Heilongjiang Medical Doctor Association
- Member, Young Physicians Committee on Lung Cancer, Heilongjiang Medical Doctor Association
- Group Leader, Palliative Care Branch, Heilongjiang Medical Association
Name order: in Chinese the family name comes first (Liu Fang). Papers usually list the name as Fang Liu or Liu F.
Selected publications
36 papers on PubMed matched by name and affiliation; 14 as first or senior author since 2016. Most recent first- or senior-author papers:
- Cell Death Differ, 2026 (senior author): A positive feedback loop between SERPINH1 and MMP-9/TGF-β1 promotes lung adenocarcinoma progression. PubMed 40819105
- Int J Med Inform, 2025 (senior author): Development of a machine learning-based prognostic model for survival prediction in patients with lung cancer brain metastases using multicenter clinical data. PubMed 40602219
- Mol Imaging Biol, 2025 (first author): (19)F MR Imaging of Dule Lung Cancer Models with Two Administration Methods of PFC Nanoparticles. PubMed 40629206
- Lung Cancer, 2025 (senior author): Neoadjuvant immunotherapy in early-stage NSCLC: navigating biomarker dilemmas and special population challenges. PubMed 40409027
- Front Immunol, 2025 (senior author): The Lung Cancer Immune Prognostic Score predicts pathologic complete response and survival in NSCLC patients receiving neoadjuvant immunochemotherapy. PubMed 40308604
- Front Immunol, 2025 (senior author): A comprehensive prognostic and immunological implications of Gremlin 1 in lung adenocarcinoma. PubMed 40066442
- Front Oncol, 2024 (senior author): The establishment of PD-1 inhibitor treatment prognosis model based on dynamic changes of peripheral blood indexes in patients with advanced lung squamous cell carcinoma. PubMed 39741972
- Proc Natl Acad Sci U S A, 2024 (senior author): SP1 undergoes phase separation and activates RGS20 expression through super-enhancers to promote lung adenocarcinoma progression. PubMed 38976739
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion